In its largest financing round to date, QuatRx Pharmaceuticals Co. brought in $44 million in a Series E round to support ongoing clinical development of two endocrine programs, including a Phase III-stage selective estrogen receptor modulator for vaginal atrophy, and an early clinical-stage lipid-lowering compound. (BioWorld Today)